Navigation Links
Watson Confirms Pataday™ Patent Challenge

PARSIPPANY, N.J., June 14, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%.  Watson's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% is a generic version of Alcon, Inc.'s Pataday™ (olopatadine hydrochloride ophthalmic solution) 0.2%, which is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Alcon Research, Ltd., Alcon Pharmaceuticals, Ltd., and Kyowa Hakko Kirin Co., Ltd. filed suit against Watson on June 9, 2011 in the United States District Court for the Southern District of Indiana seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent Nos. 5,641,805, 6,995,186, and 7,402,609.  Alcon's lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA until October 29, 2013, or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

For the twelve months ending April 30, 2011, Pataday had total U.S. sales of approximately $224 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.  

Pataday™ (olopatadine hydrochloride ophthalmic solution) 2% is a trademark of Novartis AG. CONTACTS:Investors:Patty Eisenhaur(862) 621-8141Media:Charlie Mayr(862) 621-8030(Logo:


SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
(Date:11/30/2015)... DULLES, Va. , Nov. 30, 2015  IBA ... the manufacture and distribution of radiopharmaceuticals, announced that as ... Zevacor Pharma, Inc. (Zevacor Pharma). The decision to rebrand ... of the firm as well as its close relationship ... owned by Illinois Health and Science (IHS). ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
(Date:11/30/2015)... MOUNTAIN VIEW, Calif. , Nov. 30, ... has been the norm in U.S. medical ... obsolete. The increasingly popular accountable care payer-provider ... payment models and, in their wake, alter ... or quality-based payments will push forward new ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... ... running, and walking are regular Sunday activities for many South Floridians, but their physical ... That’s when the 7th annual ANF Group Tour de Broward will take place at ... Joe DiMaggio Children’s Hospital. , The community fundraiser, sponsored by ANF Group, consists ...
(Date:11/30/2015)... ... 30, 2015 , ... HemoTreat™ has announced that the company ... to its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s Chief ... comparison chart and ingredient list allows our customers to quickly see why, and ...
(Date:11/30/2015)... ... 2015 , ... At Grand Dental PC, their priority is to deliver quality ... dental problems, you need to turn to a dentist who listens and responds; an ... a friendly dentist who counsels you on the best ways to maintain and improve ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies specializes in ... can visit Dr. Margulies to experience the best available orthodontic experience in the area. ... "NJ Top Dentist"! , Orthodontics is the branch of dentistry that specializes in the ...
(Date:11/30/2015)... ... 2015 , ... International telepathology consultations can significantly improve patient ... Diagnostics researchers. Their review of more than 1,500 pathology cases submitted electronically ... significantly altered treatment plans for more than half of the cases in which ...
Breaking Medicine News(10 mins):